Shares of Idenix Pharma Down 7+% After FDA Says Needs Added Time to Review Response Package for IDX184
Idenix (NASDAQ: IDIX) comments were from the JPMorgan Healthcare Conference last night. Idenix said an FDA response should be sometime during Q1.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.